NEWARK, Del., Sept. 18, 2008 (GLOBE NEWSWIRE) -- iBioPharma, Inc. (OTCBB:IBPM) (the "Company") announced today that the Company has selected a plant-made influenza vaccine as its first product candidate for clinical development. Favorable efficacy data from preclinical studies in the ferret model influenced the Company's decision. Ferrets are the standard species for testing the efficacy of candidate influenza vaccines prior to human clinical trials.
